wuxrteva

Washington Report

Oct 07, 2015
Pharmaceutical Executive
Managing the nomination of new commissioner adds to a packed agenda for FDA this month, writes Jill Wechsler.
Sep 09, 2015
Pharmaceutical Executive
Amarin ruling puts pressure on FDA to reassess marketing rules, writes Jill Wechsler.
Aug 05, 2015
Pharmaceutical Executive
Despite overwhelming House approval last month of the 21st Century Cures Act, bipartisan support may fall apart in the coming months, writes Jill Wechsler.
Jul 01, 2015
Pharmaceutical Executive
FDA wants pharma to be more selective in seeking special status for promising therapies, Jill Wechsler reports.
Jun 01, 2015
Pharmaceutical Executive
New proposals from Congress to spur innovation will strain resources needed for regulatory approval.
May 01, 2015
Pharmaceutical Executive
Insurers and payers demand lower prices—along with quality and innovation.
Apr 12, 2015
Pharmaceutical Executive
FDA is under pressure to moderate oversight of pharma advertising and promotion.
Mar 16, 2015
Pharmaceutical Executive
Congress, Obama offer strategies to reduce regulatory roadblocks to new breakthroughs.
Feb 01, 2015
Pharmaceutical Executive
Pressure mounts for new drug payment models and greater clarity on economic evidence.
Jan 09, 2015
Pharmaceutical Executive
Transparency, quality, collaboration key to filling pipelines, gaining reimbursement.
lorem ipsum